ArticleExperimental and therapeutic medicine2026
Cardiovascular health metrics and the risk of metabolic dysfunction-associated steatosis liver disease: A meta-analysis.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to ascertain the associations between the Life's Essential 8 (LE8) score and metabolic dysfunction-associated steatosis liver disease (MASLD) risk. The PubMed, Scopus and Cochrane library databases were searched from inception to December 2025. Data synthesis was performed using R software. The final analysis incorporated five observational studies, encompassing a total of 36,187 participants aged 18 to 70 years. The results showed that a moderate LE8 score was associated with a lower risk of MASLD compared to a low LE8 score [odds ratio (OR)=0.36, 95% confidence interval (CI): 0.25-0.52]. Furthermore, compared to the low LE8 score, a high LE8 score was indicative of a decreased risk of MASLD (OR=0.07, 95% CI: 0.02-0.19). In conclusion, this meta-analysis suggests that favorable cardiovascular health metrics may confer protection against MASLD. However, the substantial heterogeneity observed across the included studies warrants a cautious interpretation of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.